Advances in the treatment of platinum-resistant ovarian cancer with PARP inhibitors

doi:10.3760/cma.j.cn371439-20200629-00036

Abstract

Abstract:

Poly ADP-ribose polymerase(PARP)inhibitor is a targeted biological agent for the treatment of ovarian cancer, which is mainly suitable for platinum-sensitive ovarian cancer patients. However, data from clinical trials showed that PARP inhibitors have certain therapeutic effect on platinum-resistant or platinum-refractory ovarian cancer patients. It may become a new hope for treatment of ovarian cancer patients in the future.

Key words: Ovarian neoplasms, Poly(ADP-ribose) polymerase, Chemotherapy

Li Chenxi, Zhao Hongwei. Advances in the treatment of platinum-resistant ovarian cancer with PARP inhibitors[J]. Journal of International Oncology, 2021, 48(3): 180-183.

References 29

[1]	Gaona-Luviano P, Medina-Gaona LA, Magaña-Pérez K. Epidemiology of ovarian cancer [J]. Chin Clin Oncol, 2020,9(4):47. DOI: 10.21037/cco-20-34. doi: 10.21037/cco
[2]	Pujade-Lauraine E, Combe P. Recurrent ovarian cancer[J]. Ann Oncol, 2016,27 Suppl 1: i63-i65. DOI: 10.1093/annonc/mdw079.
[3]	Scott CL, Swisher EM, Kaufmann SH. Poly (ADP-ribose) polyme-rase inhibitors: recent advances and future development[J]. J Clin Oncol, 2015,33(12):1397-1406. DOI: 10.1200/JCO.2014.58.8848. doi: 10.1200/JCO.2014.58.8848 pmid: 25779564
[4]	李宁, 吴令英. PARP抑制剂在上皮性卵巢癌的应用现状[J]. 实用妇产科杂志, 2020,36(2):88-92.
[5]	Scott LJ. Niraparib: first global approval[J]. Drugs, 2017,77(9):1029-1034. DOI: 10.1007/s40265-017-0752-y.
[6]	Syed YY. Rucaparib: first global approval[J]. Drugs, 2017,77(5):585-592. DOI: 10.1007/s40265-017-0716-2. doi: 10.1007/s40265-017-0716-2 pmid: 28247266
[7]	Deeks ED. Olaparib: first global approval[J]. Drugs, 2015,75(2):231-240. DOI: 10.1007/s40265-015-0345-6. pmid: 25616434
[8]	Pujade-Lauraine E, Banerjee S, Pignata S. Management of platinum-resistant, relapsed epithelial ovarian cancer and new drug perspectives[J]. J Clin Oncol, 2019,37(27):2437-2448. DOI: 10.1200/JCO.19.00194. pmid: 31403868
[9]	Washington CR, Richardson DL, Moore KN. Olaparib in the treatment of ovarian cancer[J]. Future Oncol, 2019,15(30):3435-3449. DOI: 10.2217/fon-2019-0271. doi: 10.2217/fon-2019-0271 pmid: 31478762
[10]	Kaufman B, Shapira-Frommer R, Schmutzler RK, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation[J]. J Clin Oncol, 2015,33(3):244-250. DOI: 10.1200/JCO.2014.56.2728. pmid: 25366685
[11]	Kim H, George E, Ragland R, et al. Targeting the ATR/CHK1 axis with PARP inhibition results in tumor regression in BRCA-mutant ovarian cancer models[J]. Clin Cancer Res, 2017,23(12):3097-3108. DOI: 10.1158/1078-0432.CCR-16-2273.
[12]	Domchek SM, Aghajanian C, Shapira-Frommer R, et al. Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy[J]. Gynecol Oncol, 2016,140(2):199-203. DOI: 10.1016/j.ygyno.2015.12.020.
[13]	Jenner ZB, Sood AK, Coleman RL. Evaluation of rucaparib and companion diagnostics in the PARP inhibitor landscape for recurrent ovarian cancer therapy[J]. Future Oncol, 2016,12(12):1439-1456. DOI: 10.2217/fon-2016-0002. pmid: 27087632
[14]	Sabatucci I, Maltese G, Lepori S, et al. Rucaparib: a new treatment option for ovarian cancer[J]. Expert Opin Pharmacother, 2018,19(7):765-771. DOI: 10.1080/14656566.2018.1464557. doi: 10.1080/14656566.2018.1464557 pmid: 29672168
[15]	Dal Molin GZ, Westin SN, Coleman RL. Rucaparib in ovarian can-cer: extending the use of PARP inhibitors in the recurrent disease[J]. Future Oncol, 2018,14(30):3101-3110. DOI: 10.2217/fon-2018-0215. doi: 10.2217/fon-2018-0215 pmid: 30105925
[16]	Oza AM, Tinker AV, Oaknin A, et al. Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: integrated analysis of data from Study 10 and ARIEL2[J]. Gynecol Oncol, 2017,147(2):267-275. DOI: 10.1016/j.ygyno.2017.08.022. pmid: 28882436
[17]	Moore KN, Secord AA, Geller MA, et al. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial[J]. Lancet Oncol, 2019,20(5):636-648. DOI: 10.1016/S1470-2045(19)30029-4. doi: 10.1016/S1470-2045(19)30029-4 pmid: 30948273
[18]	Moore KN, Secord AA, Geller MA, et al. QUADRA: a phase Ⅱ, open-label, single-arm study to evaluate niraparib in patients (pts) with relapsed ovarian cancer (ROC) in 4th or later line of therapy: results from the tBRCAmut subset[J]. Ann Oncol, 2018,29(suppl 8):944P.DOI: 10.1093/annonc/mdy285.152.
[19]	Perez-Fidalgo JA, Iglesias M, Bohn U, et al. GEICO1601-ROLANDO: a multicentric single arm phase Ⅱ clinical trial to evaluate the combination of olaparib and pegylated liposomal doxorubicin for platinum-resistant ovarian cancer[J]. Future Sci OA, 2019,5(2):FSO370. DOI: 10.4155/fsoa-2018-0107. pmid: 30820349
[20]	Konstantinopoulos PA, Barry WT, Birrer M, et al. Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial[J]. Lancet Oncol, 2019,20(4):570-580. DOI: 10.1016/S1470-2045(18)30905-7. doi: 10.1016/S1470-2045(18)30905-7 pmid: 30880072
[21]	薛晨, 赵月, 石光, 等. PD-1/PD-L1抑制剂在卵巢癌中的研究进展[J]. 国际肿瘤学杂志, 2020,47(5):312-315. DOI: 10.3760/cma.j.cn371439-20200321-00026.
[22]	Shen J, Zhao W, Ju Z, et al. PARPi triggers the STING-dependent immune response and enhances the therapeutic efficacy of immune checkpoint blockade independent of BRCAness[J]. Cancer Res, 2019,79(2):311-319. DOI: 10.1158/0008-5472.CAN-18-1003. doi: 10.1158/0008-5472.CAN-18-1003 pmid: 30482774
[23]	Konstantinopoulos PA, Waggoner S, Vidal GA, et al. Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma[J]. JAMA Oncol, 2019,5(8):1141-1149. DOI: 10.1001/jamaoncol.2019.1048. doi: 10.1001/jamaoncol.2019.1048
[24]	Varga A, Piha-Paul S, Ott PA, et al. Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: analysis of KEYNOTE-028[J]. Gynecol Oncol, 2019,152(2):243-250. DOI: 10.1016/j.ygyno.2018.11.017. doi: 10.1016/j.ygyno.2018.11.017
[25]	Matulonis UA, Shapira-Frommer R, Santin AD, et al. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase Ⅱ KEYNOTE-100 study[J]. Ann Oncol, 2019,30(7):1080-1087. DOI: 10.1093/annonc/mdz135. doi: 10.1093/annonc/mdz135 pmid: 31046082
[26]	Ivy SP, Liu JF, Lee JM, et al. Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer[J]. Expert Opin Investig Drugs, 2016,25(5):597-611. DOI: 10.1517/13543784.2016.1156857. doi: 10.1517/13543784.2016.1156857 pmid: 26899229
[27]	Liu JF, Tolaney SM, Birrer M, et al. A phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer[J]. Eur J Cancer, 2013,49(14):2972-2978. DOI: 10.1016/j.ejca.2013.05.020. doi: 10.1016/j.ejca.2013.05.020 pmid: 23810467
[28]	Liu JF, Barry WT, Birrer M, et al. Overall survival and updated progression-free survival outcomes in a randomized phase Ⅱ study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer[J]. Ann Oncol, 2019,30(4):551-557. DOI: 10.1093/annonc/mdz018. doi: 10.1093/annonc/mdz018 pmid: 30753272
[29]	Boussios S, Karihtala P, Moschetta M, et al. Combined strategies with poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer: a literature review[J]. Diagnostics (Basel), 2019,9(3):87. DOI: 10.3390/diagnostics9030087.